Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry

HC. Kluin-Nelemans, A. Reiter, A. Illerhaus, B. van Anrooij, K. Hartmann, LFR. Span, A. Gorska, M. Niedoszytko, M. Lange, L. Scaffidi, R. Zanotti, P. Bonadonna, C. Perkins, C. Elena, L. Malcovati, K. Shoumariyeh, N. von Bubnoff, R. Parente, M....

. 2020 ; 34 (4) : 1090-1101. [pub] 20191118

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20025115

Grantová podpora
F 4701 Austrian Science Fund FWF - Austria
F 4704 Austrian Science Fund FWF - Austria

Systemic mastocytosis (SM) is frequently associated with eosinophilia. To examine its prevalence and clinical impact in all WHO classification-based subcategories, we analyzed eosinophil counts in 2350 mastocytosis patients using the dataset of the European Competence Network on Mastocytosis. Ninety percent of patients had normal eosinophil counts, 6.8% mild eosinophilia (0.5-1.5 × 109/l), and 3.1% hypereosinophilia (HE; >1.5 × 109/l). Eosinophilia/HE were mainly present in patients with advanced SM (17%/19%), and only rarely recorded in patients with indolent and smoldering SM (5%/1%), and some patients with cutaneous mastocytosis. The eosinophil count correlated with organomegaly, dysmyelopoiesis, and the WHO classification, but not with mediator-related symptoms or allergy. Eosinophilia at diagnosis had a strong prognostic impact (p < 0.0001) on overall survival (OS) and progression-free survival (PFS), with a 10-year OS of 19% for patients with HE, 70% for those with mild eosinophilia, and 88% for patients with normal eosinophil counts. In 89% of patients with follow-up data (n = 1430, censored at start of cytoreductive therapy), eosinophils remained stable. In those with changing eosinophil counts (increase/decrease or mixed pattern), OS and PFS were inferior compared with patients with stable eosinophil counts. In conclusion, eosinophilia and HE are more prevalent in advanced SM and are predictors of a worse outcome.

3 Medizinische Klinik Universitätsmedizin Mannheim Universität Heidelberg Mannheim Germany

Allergy Unit Verona University Hospital Verona Italy

Department Immunol Genetics and Pathology Uppsala University Hospital Uppsala University Uppsala Sweden

Department of Allergology Medical University of Gdansk Gdańsk Poland

Department of Dermatology and Allergy Biederstein School of Medicine Technical University of Munich Munich Germany

Department of Dermatology and Venereology Medical University of Graz Graz Austria

Department of Dermatology and Venerology Kepler University Hospital Johannes Kepler University Linz Austria

Department of Dermatology Medical Center University of Freiburg Freiburg Germany Faculty of Medicine University of Freiburg Freiburg Germany Department of Dermatology and Allergy Justus Liebig University Giessen Giessen Germany

Department of Dermatology University Hospitals Leuven Leuven Belgium

Department of Dermatology University of Cologne Cologne Germany

Department of Dermatology University of Cologne Cologne Germany Division of Allergy Department of Dermatology University of Basel Basel Switzerland

Department of Dermatology Venereology and Allergology Medical University of Gdansk Gdańsk Poland

Department of Hematology Gustave Roussy Cancer Center Villejuif France

Department of Hematology Oncology and Stem Cell Transplantation Medical Center Faculty of Medicine University of Freiburg Freiburg Germany German Cancer Consortium Partner Site Freiburg Freiburg Germany

Department of Hematology Oncology and Stem Cell Transplantation Medical Center Faculty of Medicine University of Freiburg Freiburg Germany German Cancer Consortium Partner Site Freiburg Freiburg Germany Department of Hematology and Oncology Medical Center University of Schleswig Holstein Campus Lübeck Lübeck Germany

Department of Hematology Semmelweis University Budapest Hungary

Department of Hematology University Medical Center Groningen University of Groningen Groningen The Netherlands

Department of Hematology University Medical Center Groningen University of Groningen Groningen The Netherlands Department of Internal Medicine Section Allergology University Medical Center Groningen University of Groningen Groningen The Netherlands

Department of Internal Medicine 1 Division of Hematology and Hemostaseology Vienna Austria Ludwig Boltzmann Cluster Oncology Medical University of Vienna Vienna Austria

Department of Molecular Medicine and Department of Hematology Oncology University of Pavia and Fondazione IRCCS Policlinico San Matteo Pavia Italy

Department of Oncology Haematology Haemostaseology and Stem Cell Transplantation University Hospital RWTH Aachen Aachen Germany

Division of Allergy and Clinical Immunology University of Salerno Salerno Italy

Division of Hematology Department of Medicine Stanford University School of Medicine Stanford CA USA

Division of Hematology Istanbul Medical School University of Istanbul Istanbul Turkey

Faculty of Medicine and Health Sciences Department of Immunology Allergology Rheumatology University of Antwerp and Antwerp University Hospital Antwerpen Belgium

French Reference Center for Mastocytosis Hôpital Necker Assistance Publique Hôpitaux de Paris Imagine Institute University Paris Descartes Paris France

Laboratory of Hematology Pitié Salpêtrière Hospital Paris France

Necker Pasteur Center for Infectious Diseases and Tropical Medicine Paris Descartes University Paris France

Pediatric Dermatology Unit Department of Medicine University of Padova Padova Italy

Section of Hematology Department of Medicine Verona University Hospital Verona Italy

University Clinic for Hematology and Oncology Johannes Kepler University Linz Austria

University Hospital Brno Brno Czech Republic

University Hospital of Leipzig Leipzig Germany Aiichi Medical University Nagakute Japan

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20025115
003      
CZ-PrNML
005      
20201222153706.0
007      
ta
008      
201125s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41375-019-0632-4 $2 doi
035    __
$a (PubMed)31740811
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Kluin-Nelemans, Hanneke C $u Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. j.c.kluin@umcg.nl.
245    10
$a Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry / $c HC. Kluin-Nelemans, A. Reiter, A. Illerhaus, B. van Anrooij, K. Hartmann, LFR. Span, A. Gorska, M. Niedoszytko, M. Lange, L. Scaffidi, R. Zanotti, P. Bonadonna, C. Perkins, C. Elena, L. Malcovati, K. Shoumariyeh, N. von Bubnoff, R. Parente, M. Triggiani, J. Schwaab, M. Jawhar, F. Caroppo, AB. Fortina, K. Brockow, A. Zink, D. Fuchs, A. Kilbertus, AS. Yavuz, M. Doubek, M. Mattsson, H. Hagglund, J. Panse, V. Sabato, E. Aberer, D. Niederwieser, C. Breynaert, J. Várkonyi, V. Kennedy, O. Lortholary, T. Jakob, O. Hermine, J. Rossignol, M. Arock, J. Gotlib, P. Valent, WR. Sperr,
520    9_
$a Systemic mastocytosis (SM) is frequently associated with eosinophilia. To examine its prevalence and clinical impact in all WHO classification-based subcategories, we analyzed eosinophil counts in 2350 mastocytosis patients using the dataset of the European Competence Network on Mastocytosis. Ninety percent of patients had normal eosinophil counts, 6.8% mild eosinophilia (0.5-1.5 × 109/l), and 3.1% hypereosinophilia (HE; >1.5 × 109/l). Eosinophilia/HE were mainly present in patients with advanced SM (17%/19%), and only rarely recorded in patients with indolent and smoldering SM (5%/1%), and some patients with cutaneous mastocytosis. The eosinophil count correlated with organomegaly, dysmyelopoiesis, and the WHO classification, but not with mediator-related symptoms or allergy. Eosinophilia at diagnosis had a strong prognostic impact (p < 0.0001) on overall survival (OS) and progression-free survival (PFS), with a 10-year OS of 19% for patients with HE, 70% for those with mild eosinophilia, and 88% for patients with normal eosinophil counts. In 89% of patients with follow-up data (n = 1430, censored at start of cytoreductive therapy), eosinophils remained stable. In those with changing eosinophil counts (increase/decrease or mixed pattern), OS and PFS were inferior compared with patients with stable eosinophil counts. In conclusion, eosinophilia and HE are more prevalent in advanced SM and are predictors of a worse outcome.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a eozinofilie $x komplikace $x patologie $7 D004802
650    _2
$a eozinofily $x patologie $7 D004804
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a kojenec $7 D007223
650    _2
$a novorozenec $7 D007231
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mastocytóza $x etiologie $x mortalita $x patologie $7 D008415
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prognóza $7 D011379
650    _2
$a míra přežití $7 D015996
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Reiter, Andreas $u III. Medizinische Klinik, Universitätsmedizin Mannheim, Universität Heidelberg, Mannheim, Germany.
700    1_
$a Illerhaus, Anja $u Department of Dermatology, University of Cologne, Cologne, Germany.
700    1_
$a van Anrooij, Bjorn $u Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. Department of Internal Medicine, Section Allergology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
700    1_
$a Hartmann, Karin $u Department of Dermatology, University of Cologne, Cologne, Germany. Division of Allergy, Department of Dermatology, University of Basel, Basel, Switzerland.
700    1_
$a Span, Lambertus F R $u Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
700    1_
$a Gorska, Aleksandra $u Department of Allergology, Medical University of Gdansk, Gdańsk, Poland.
700    1_
$a Niedoszytko, Marek $u Department of Allergology, Medical University of Gdansk, Gdańsk, Poland.
700    1_
$a Lange, Magdalena $u Department of Dermatology, Venereology and Allergology, Medical University of Gdansk, Gdańsk, Poland.
700    1_
$a Scaffidi, Luigi $u Section of Hematology, Department of Medicine, Verona University Hospital, Verona, Italy.
700    1_
$a Zanotti, Roberta $u Section of Hematology, Department of Medicine, Verona University Hospital, Verona, Italy.
700    1_
$a Bonadonna, Patrizia $u Allergy Unit, Verona University Hospital, Verona, Italy.
700    1_
$a Perkins, Cecelia $u Division of Hematology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
700    1_
$a Elena, Chiara $u Department of Molecular Medicine and Department of Hematology Oncology, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
700    1_
$a Malcovati, Luca $u Department of Molecular Medicine and Department of Hematology Oncology, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
700    1_
$a Shoumariyeh, Khalid $u Department of Hematology, Oncology and Stem Cell Transplantation, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany. German Cancer Consortium (DKTK) Partner Site Freiburg, Freiburg, Germany.
700    1_
$a von Bubnoff, Nikolas $u Department of Hematology, Oncology and Stem Cell Transplantation, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany. German Cancer Consortium (DKTK) Partner Site Freiburg, Freiburg, Germany. Department of Hematology and Oncology, Medical Center, University of Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.
700    1_
$a Parente, Roberta $u Division of Allergy and Clinical Immunology, University of Salerno, Salerno, Italy.
700    1_
$a Triggiani, Massimo $u Division of Allergy and Clinical Immunology, University of Salerno, Salerno, Italy.
700    1_
$a Schwaab, Juliana $u III. Medizinische Klinik, Universitätsmedizin Mannheim, Universität Heidelberg, Mannheim, Germany.
700    1_
$a Jawhar, Mohamad $u III. Medizinische Klinik, Universitätsmedizin Mannheim, Universität Heidelberg, Mannheim, Germany.
700    1_
$a Caroppo, Francesca $u Pediatric Dermatology Unit, Department of Medicine, University of Padova, Padova, Italy.
700    1_
$a Fortina, Anna Belloni $u Pediatric Dermatology Unit, Department of Medicine, University of Padova, Padova, Italy.
700    1_
$a Brockow, Knut $u Department of Dermatology and Allergy Biederstein, School of Medicine, Technical University of Munich, Munich, Germany.
700    1_
$a Zink, Alexander $u Department of Dermatology and Allergy Biederstein, School of Medicine, Technical University of Munich, Munich, Germany.
700    1_
$a Fuchs, David $u University Clinic for Hematology and Oncology, Johannes Kepler University, Linz, Austria.
700    1_
$a Kilbertus, Alex $u Department of Dermatology and Venerology, Kepler University Hospital, Johannes Kepler University, Linz, Austria.
700    1_
$a Yavuz, Akif Selim $u Division of Hematology, Istanbul Medical School, University of Istanbul, Istanbul, Turkey.
700    1_
$a Doubek, Michael $u University Hospital Brno, Brno, Czech Republic.
700    1_
$a Mattsson, Mattias $u Department Immunol, Genetics and Pathology (MM) and Dept Hematol (MM, HH), Uppsala University Hospital, Uppsala University, Uppsala, Sweden.
700    1_
$a Hagglund, Hans $u Department Immunol, Genetics and Pathology (MM) and Dept Hematol (MM, HH), Uppsala University Hospital, Uppsala University, Uppsala, Sweden.
700    1_
$a Panse, Jens $u Department of Oncology, Haematology, Haemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany.
700    1_
$a Sabato, Vito $u Faculty of Medicine and Health Sciences, Department of Immunology-Allergology-Rheumatology, University of Antwerp and Antwerp University Hospital, Antwerpen, Belgium.
700    1_
$a Aberer, Elisabeth $u Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria.
700    1_
$a Niederwieser, Dietger $u University Hospital of Leipzig, Leipzig, Germany. Aiichi Medical University, Nagakute, Japan.
700    1_
$a Breynaert, Christine $u Department of Dermatology, University Hospitals Leuven, Leuven, Belgium.
700    1_
$a Várkonyi, Judit $u Department of Hematology, Semmelweis University, Budapest, Hungary.
700    1_
$a Kennedy, Vanessa $u Division of Hematology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
700    1_
$a Lortholary, Olivier $u Necker Pasteur Center for Infectious Diseases and Tropical Medicine, Paris Descartes University, Paris, France.
700    1_
$a Jakob, Thilo $u Department of Dermatology, Medical Center, University of Freiburg, Freiburg, Germany. Faculty of Medicine, University of Freiburg, Freiburg, Germany. Department of Dermatology and Allergy, Justus-Liebig University Giessen, Giessen, Germany.
700    1_
$a Hermine, Olivier $u French Reference Center for Mastocytosis (CEREMAST), Hôpital Necker, Assistance Publique Hôpitaux de Paris, Imagine Institute, University Paris Descartes, Paris, France.
700    1_
$a Rossignol, Julien $u Department of Hematology, Gustave Roussy Cancer Center, Villejuif, France.
700    1_
$a Arock, Michel $u Laboratory of Hematology, Pitié-Salpêtrière Hospital, Paris, France.
700    1_
$a Gotlib, Jason $u Division of Hematology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
700    1_
$a Valent, Peter $u Department of Internal Medicine I, Division of Hematology and Hemostaseology, Vienna, Austria. Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria.
700    1_
$a Sperr, Wolfgang R $u Department of Internal Medicine I, Division of Hematology and Hemostaseology, Vienna, Austria. Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria.
773    0_
$w MED00003138 $t Leukemia $x 1476-5551 $g Roč. 34, č. 4 (2020), s. 1090-1101
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31740811 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201222153701 $b ABA008
999    __
$a ok $b bmc $g 1599260 $s 1115801
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 34 $c 4 $d 1090-1101 $e 20191118 $i 1476-5551 $m Leukemia $n Leukemia $x MED00003138
GRA    __
$a F 4701 $p Austrian Science Fund FWF $2 Austria
GRA    __
$a F 4704 $p Austrian Science Fund FWF $2 Austria
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace